Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL) in North America. Because of the heterogeneity of the disease, treatment options vary. In Canada, no unified national guideline exists for the front-line treatment of FL; provincial guidelines vary and are largely based on funding. There is therefore a need for evidence-based national treatment guidelines that are supported by Canadian hematologists to ensure that patients with FL have equitable access to the best available care. A group of experts from across Canada developed a national evidence-based treatment guideline to provide health care professionals with clear guidance on the first-line management of FL.
We would like to express our thanks to the hematologists and medical oncologists who provided their clinical expertise throughout the development of these guidelines:
Dr. John Kuruvilla, Hematologist, Princess Margaret Cancer Centre, Ontario
Dr. Sarit Assouline, hematologist, McGill University and Jewish General Hospital, Quebec.
Dr. David Hodgson, Radiation Oncologist, Princess Margaret Hospital, Ontario.
Dr. David MacDonald, Hematologist, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Nova Scotia.
Dr. Douglas Stewart, Hematologist, Tom Baker Cancer Centre, Alberta.
Anna Christofides, New Evidence, Toronto, Ontario, Canada
Marina Komolova, New Evidence, Toronto, Ontario, Canada
Dr. Joseph Connors, Hematologist, BC Cancer Agency, British Columbia.
Follow us on Social Media to stay up to date and informed on all things Lymphoma Canada!